The heterogeneous course of drug transit through the body

Trends in Pharmacological Sciences

Volumn 25, Issue 3, 2004, Pages 140-146

  Dokoumetzidis, Aristides ^a,c   Karalis, Vangelis ^a   Iliadis, Athanassios ^b   Macheras, Panos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHAOTIC DYNAMICS; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG DISPOSITION; DRUG EFFECT; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUBILITY; FRACTAL ANALYSIS; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRANSIT; HUMAN; NONLINEAR SYSTEM; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STOCHASTIC MODEL;

EID: 1342328081     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.01.008     Document Type: Article

References (67)

1. ben-Avraham D., Havlin S. Diffusion and Reactions in Fractals and Disordered Systems. 2000;Cambridge University Press.
2. Bassingthwaighte J.B., et al. Fractal Physiology. 1994;Oxford University Press.
3. Kopelman R. Fractal reaction kinetics. Science. 241:1988;1620-1626.
4. Bhaskar K.R., et al. Viscous fingering of HCl through gastric mucin. Nature. 360:1992;458-461.
5. Holm L., Flemstrom G. Microscopy of acid transport at the gastric surface in vivo. J. Intern. Med. Suppl. 732:1990;91-95.
6. Lenormand R., et al. Three-dimensional fractals: experimental measurements using capillary effects. Phys. Rev. A. 36:1987;1855-1858.
7. Daccord G. Chemical dissolution of a porous medium by a reactive fluid. Phys. Rev. Lett. 58:1987;479-482.
8. Nittmann J., et al. Fractal growth of viscous fingers - quantitative characterization of a fluid instability phenomenon. Nature. 314:1985;141-144.
9. Macheras P., Argyrakis P. Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Pharm. Res. 14:1997;842-847.
10. Kalampokis A., et al. Heterogeneous tube model for the study of small intestinal transit flow. Pharm. Res. 16:1999;87-91.
11. Kalampokis A., et al. A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts. Pharm. Res. 16:1999;1764-1769.
12. Caroli-Bosc F.X., et al. Ursodeoxycholic acid modulates cyclosporin A oral absorption in liver transplant recipients. Fundam. Clin. Pharmacol. 14:2000;601-609.
13. Higaki K., et al. Time-dependent oral absorption models. J. Pharmacokinet. Pharmacodyn. 28:2001;109-128.
14. Dokoumetzidis A., Macheras P. A population growth model of dissolution. Pharm. Res. 14:1997;1122-1126.
15. Valsami G., et al. Modeling of supersaturated dissolution data. Int. J. Pharm. 181:1999;153-157.
16. Lansky P., Weiss M. Does the dose-solubility ratio affect the mean dissolution time of drugs? Pharm. Res. 16:1999;1470-1476.
17. Lansky P., Weiss M. Modeling heterogeneity of properties and random effects in drug dissolution. Pharm. Res. 18:2001;1061-1067.
18. Lansky P., Weiss M. Classification of dissolution profiles in terms of fractional dissolution rate and a novel measure of heterogeneity. J. Pharm. Sci. 92:2003;1632-1647.
19. Macheras P., Dokoumetzidis A. On the heterogeneity of drug dissolution and release. Pharm. Res. 17:2000;108-112.
20. Kosmidis K., et al. A reappraisal of drug release laws using Monte Carlo simulations: the prevalence of the Weibull function. Pharm. Res. 20:2003;988-995.
21. Kosmidis K., et al. Fractal kinetics in drug release from finite fractal matrices. J. Chem. Phys. 119:2003;6373-6377.
22. West G.B., et al. A general model for the origin of allometric scaling laws in biology. Science. 276:1997;122-126.
23. West G.B., et al. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science. 284:1999;1677-1679.
24. Dokoumetzidis A., Macheras P. A tube model for transport and dispersion in the circulatory system based on the vascular fractal tree. Ann. Biomed. Eng. 31:2003;284-293.
25. Karalis V., et al. A physiologically based approach for the estimation of recirculatory parameters. J. Pharmacol. Exp. Ther. 308:2004;198-205.
26. Rowland M., et al. Clinical Pharmacokinetics: Concepts and Applications. 3rd Edn:1995;Williams & Wilkins, Lippincott.
27. Karalis V., et al. Fractal volume of drug distribution: it scales proportionally to body mass. Pharm. Res. 18:2001;1056-1060.
28. Karalis V., Macheras P. Drug disposition viewed in terms of the fractal volume of distribution. Pharm. Res. 19:2002;696-703.
29. Karalis V., et al. Multivariate statistics of disposition pharmacokinetic parameters for structurally unrelated drugs used in therapeutics. Pharm. Res. 19:2002;1827-1834.
30. Karalis V., et al. Quantitative structure pharmacokinetic relationships for disposition parameters of cephalosporins. Eur. J. Pharm. Sci. 20:2003;115-123.
31. Rescigno A. The rise and fall of compartmental analysis. Pharmacol. Res. 44:2001;337-342.
32. Wise M.E., Borsboom J.M. Two exceptional sets of physiological clearance curves and their mathematical form: test cases? Bull. Math. Biol. 51:1989;579-596.
33. Matis J.H., Wehrly T.E. A general approach to non-Markovian compartmental models. J. Pharmacokinet. Biopharm. 26:1998;437-456.
34. Weiss G.H., et al. A non-Markovian model for calcium kinetics in the body. J. Pharmacokinet. Biopharm. 22:1994;367-379.
35. Macheras P. A fractal approach to heterogeneous drug distribution: calcium pharmacokinetics. Pharm. Res. 13:1996;663-670.
36. Weiss M. The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping. J. Pharmacokinet. Biopharm. 27:1999;383-396.
37. Kopf M., et al. Anomalous diffusion of water in biological tissues. Biophys. J. 70:1996;2950-2958.
38. Matis J.H., Kiffe T.R. Stochastic population models. A compartmental perspective. Bickel P., et al. Lecture Notes in Statistics. Vol. 145:2000;17-37 Springer Verlag.
39. Matis J.H., et al. Some generalized stochastic compartment models for digesta flow. Biometrics. 45:1989;703-720.
40. Claret L., et al. A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin. J. Pharmacokinet. Pharmacodyn. 28:2001;445-463.
41. López-Quintela M., Casado J. Revision of the methodology in enzyme kinetics: a fractal approach. J. Theor. Biol. 139:1989;129-139.
42. Savageau M.A. Michaelis-Menten mechanism reconsidered: implications of fractal kinetics. J. Theor. Biol. 176:1995;115-124.
43. Savageau M.A. Development of fractal kinetic theory for enzyme-catalysed reactions and implications for the design of biochemical pathways. Biosystems. 47:1998;9-36.
44. Berry H. Monte Carlo simulations of enzyme reactions in two dimensions: fractal kinetics and spatial segregation. Biophys. J. 83:2002;1891-1901.
45. Fuite J., et al. Fractal pharmacokinetics of the drug mibefradil in the liver. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 66:2002;021904.
46. Derendorf H., Meibohm B. Modeling pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res. 16:1999;176-185.
47. Dokoumetzidis A., et al. Nonlinear dynamics and chaos theory: concepts and applications relevant to pharmacodynamics. Pharm. Res. 18:2001;415-426.
48. van Rossum J.M., de Bie J.E. Chaos and illusion. Trends Pharmacol. Sci. 12:1991;379-383.
49. Yambe T., et al. Chaos attractors of ventricular elastance to evaluate cardiac performance. Artif. Organs. 27:2003;104-107.
50. Tulppo M.P., et al. Effects of pharmacological adrenergic and vagal modulation on fractal heart rate dynamics. Clin. Physiol. 21:2001;515-523.
51. Weiss J.N., et al. Chaos and the transition to ventricular fibrillation: a new approach to antiarrhythmic drug evaluation. Circulation. 99:1999;2819-2826.
52. Garfinkel A., et al. Preventing ventricular fibrillation by flattening cardiac restitution. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6061-6066.
53. Fenton F.H., et al. Multiple mechanisms of spiral wave breakup in a model of cardiac electrical activity. Chaos. 12:2002;852-892.
54. Widman G., et al. Quantification of depth of anesthesia by nonlinear time series analysis of brain electrical activity. Phys. Rev. E Stat. Phys. Plasmas Fluids Relat. Interdiscip Topics. 62:2000;4898-4903.
55. Lehnertz K. Non-linear time series analysis of intracranial EEG recordings in patients with epilepsy-an overview. Int. J. Psychophysiol. 34:1999;45-52.
56. Elger C.E. Nonlinear EEG analysis and its potential role in epileptology. Epilepsia. 41:2000;S34-S38.
57. Di Mascio M., et al. Decreased chaos of midbrain dopaminergic neurons after serotonin denervation. Neuroscience. 92:1999;237-243.
58. Ishizuka S., Hayashi H. Spontaneous epileptiform bursts and long-term potentiation in rat CA3 hippocampal slices induced by chaotic stimulation of mossy fibers. Brain Res. 790:1998;108-114.
59. Glass L., Mackey M. From Clocks to Chaos. The Rhythms of Life. 1988;Princeton University Press.
60. Rattanakul C., et al. Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy. Biosystems. 70:2003;55-72.
61. Tolic I.M., et al. Modeling the insulin-glucose feedback system: the significance of pulsatile insulin secretion. J. Theor. Biol. 207:2000;361-375.
62. Dokoumetzidis A., et al. Nonlinear dynamics in clinical pharmacology: the paradigm of cortisol secretion and suppression. Br. J. Clin. Pharmacol. 54:2002;21-29.
63. Zuideveld K., et al. A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281:2001;R2059-R2071.
64. Kroll M.H. Biological variation of glucose and insulin includes a deterministic chaotic component. Biosystems. 50:1999;189-201.
65. Ilias I. Complexity and non-linear description of diurnal cortisol and growth hormone secretory patterns before and after sleep deprivation. Endocr. Regul. 36:2002;63-72.
66. Veldhuis J.D., Pincus S.M. Orderliness of hormone release patterns: a complementary measure to conventional pulsatile and circadian analyses. Eur. J. Endocrinol. 138:1998;358-362.
67. Veldhuis J.D., et al. Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women. J. Clin. Endocrinol. Metab. 87:2002;859-866.